Physician profile
Mark Bryant
NPI 1508860099
$1,468.88
in general payments reported to CMS, 2019-2025
12 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Occupational Vision provider received nationally (typical 2025 total: $169).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $40.09 · 2021: $223 · 2022: $597 · 2023: $198 · 2024: $35.97 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $358.73 | 2022-2025 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $288.05 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $205.51 | 2021-2022 | |
| Dompe US, INC. | $147.49 | 2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $139.23 | 2022 | |
| Abbvie INC. | $129.15 | 2022-2023 | Xen Glaucoma Treatment System |
| Novartis Pharmaceuticals Corporation | $108.96 | 2021-2022 | |
| Alcon Vision LLC | $27.57 | 2022-2025 | Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.55 | 2019 | |
| Bausch & Lomb Americas INC. | $16.57 | 2025 | Xiidra |
| Shire North American Group INC | $11.78 | 2019 | |
| Biotissue Holdings INC. | $11.29 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.